Intensity Therapeutics, Inc. (INTS )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol INTS
- Company Intensity Therapeutics, Inc.
- Price $1.3
- Changes Percentage -28.18
- Change -0.51
- Day Low $1.27
- Day High $1.82
- Year High $5.28
- Year Low $1.27
- Market Cap $19,735,229
- Price Avg 50 EMA (D) $2.08
- Price Avg 200 EMA (D) $3.07
- Exchange NASDAQ
- Volume 572,331
- Average Volume 35,188
- Open $1.77
- Previous Close $1.81
- EPS -1.17
- PE -1.11
- Earnings Announcement 2025-05-08 12:00:00
- Shares Outstanding $15,180,945
Company brief: INTENSITY THERAPEUTICS, INC. (INTS )
- Healthcare
- Biotechnology
- Mr. Lewis H. Bender M.A., M.B.A., M.S.
- https://www.intensitytherapeutics.com
- US
- N/A
- 06-30-2023
- US45828J1034
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.